Centre National de Référence des Herpèsvirus, CHU Limoges, Limoges, France; UF9481 Bioinformatique, CHU Limoges, Limoges, France; UF8843 Génomique médicale, CHU Limoges, Limoges, France; Inserm, U1092, RESINFIT, Université de Limoges, Limoges, France.
Centre National de Référence des Herpèsvirus, CHU Limoges, Limoges, France; UF8843 Génomique médicale, CHU Limoges, Limoges, France.
Antiviral Res. 2024 Nov;231:106016. doi: 10.1016/j.antiviral.2024.106016. Epub 2024 Sep 28.
A comprehensive and accessible Herpesvirus drug resistance database was designed to serve as an international reference for diagnosis and clinical studies. This database available at https://www.unilim.fr/cnr-herpesvirus/outils/codexmv/includes both resistance-related mutations and natural polymorphisms. Initially designed for human cytomegalovirus, it will be expanded to include herpes simplex and varicella-zoster viruses. Newly published mutations and new mutations reported by users or collaborating expert laboratories will be reviewed by an international committee of reference laboratories before inclusion in the database. Coupled with the Herpesvirus Sequence Analysis tool (HSA) mutation reports from NGS or Sanger sequences, it will be an open source for researchers in the field of Herpesviruses. We hope to fill this unmet need for the development and standardization of resistance genotyping.
我们设计了一个综合性且易于访问的疱疹病毒耐药性数据库,旨在为诊断和临床研究提供国际参考。该数据库位于 https://www.unilim.fr/cnr-herpesvirus/outils/codexmv/,其中包含与耐药性相关的突变和自然多态性。最初是为人类巨细胞病毒设计的,它将扩展到包括单纯疱疹病毒和水痘-带状疱疹病毒。新发表的突变和用户或合作专家实验室报告的新突变,将在被纳入数据库之前,由一个国际参考实验室委员会进行审查。与来自 NGS 或 Sanger 序列的疱疹病毒序列分析工具 (HSA) 突变报告相结合,它将成为疱疹病毒领域研究人员的开源资源。我们希望满足耐药性基因分型发展和标准化的这一未满足需求。